[sentNum: 1]<Annotation Id="12920" Type="Sentence" StartNode="0" EndNode="61">Breast-Cancer Screening &#x2014; Viewpoint of the IARC Working GroupPreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Published Comment SemanticType:[inpr] PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Working Group SemanticType:[popg] POS:JJ POS:NN POS:VBG POS:CD POS:NN POS:IN POS:DT POS:NN POS:NNP POS:NNP 
[sentNum: 2]<Annotation Id="12921" Type="Sentence" StartNode="67" EndNode="206">To the Editor: The report from the International Agency for Research on Cancer (IARC) (June 11 issue)1 does not represent expert consensus. PreferredName:Editor SemanticType:[ocdi] PreferredName:Report (document) SemanticType:[inpr] PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Issue (document) SemanticType:[inpr] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Representation (action) SemanticType:[acty] PreferredName:Consensus SemanticType:[socb] POS:TO POS:DT POS:NNP POS:: POS:DT POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:IN POS:NNP POS:CD POS:NN POS:CD POS:CD POS:NNP POS:CD POS:NN POS:NN POS:CD POS:VBZ POS:RB POS:VB POS:NN POS:NN POS:. 
[sentNum: 3]<Annotation Id="12922" Type="Sentence" StartNode="207" EndNode="344">The authors of reports that question breast-cancer screening and were published in major medical journals were not included in the panel.PreferredName:Journalist SemanticType:[prog] PreferredName:Reporting SemanticType:[hlca] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Major medical SemanticType:[idcn] PreferredName:Journal SemanticType:[inpr, mnob] PreferredName:Negation SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Laboratory Order Panels SemanticType:[inpr] POS:DT POS:NNS POS:IN POS:NNS POS:IN POS:NN POS:NN POS:NN POS:CC POS:VBD POS:VBN POS:IN POS:JJ POS:JJ POS:NNS POS:VBD POS:RB POS:VBN POS:IN POS:DT POS:NN POS:. 
[sentNum: 4]<Annotation Id="12923" Type="Sentence" StartNode="348" EndNode="475">Reductions in breast-cancer&#x2013;related mortality among young women never exposed to screening exceed those in screened age groups.2PreferredName:Reduction - action SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Young SemanticType:[tmco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Never (frequency) SemanticType:[tmco] PreferredName:Exposure to SemanticType:[clna] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Age SemanticType:[orga] PreferredName:Group 2 SemanticType:[inpr] POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:RB POS:VBN POS:TO POS:VBG POS:VB POS:DT POS:IN POS:VBN POS:NN POS:NNS POS:. 
[sentNum: 5]<Annotation Id="12924" Type="Sentence" StartNode="475" EndNode="642">2-5 In Norway and Denmark, reductions in breast-cancer&#x2013; related mortality were similar among regions that introduced screening early and those that introduced it late.5PreferredName:Norway SemanticType:[geoa] PreferredName:Denmark SemanticType:[geoa] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Similarity SemanticType:[qlco] PreferredName:Geographic Locations SemanticType:[geoa] PreferredName:Introduces SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Early SemanticType:[tmco] PreferredName:Introduces SemanticType:[ftcn] PreferredName:Late SemanticType:[tmco] POS:LS POS:: POS:CD POS:IN POS:NNP POS:CC POS:NNP POS:, POS:NNS POS:IN POS:JJ POS:JJ POS:NN POS:VBD POS:JJ POS:IN POS:NNS POS:WDT POS:VBD POS:JJ POS:JJ POS:CC POS:DT POS:WDT POS:VBD POS:PRP POS:RB POS:. 
[sentNum: 6]<Annotation Id="12925" Type="Sentence" StartNode="642" EndNode="709">5 Improved treatment, not screening, caused most of the reductions. PreferredName:Better SemanticType:[qlco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Most SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] POS:CD POS:JJ POS:NN POS:, POS:RB POS:VBG POS:, POS:VBD POS:JJS POS:IN POS:DT POS:NNS POS:. 
[sentNum: 7]<Annotation Id="12926" Type="Sentence" StartNode="710" EndNode="766">The IARC estimate leaves no room for a treatment effect. PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Estimated SemanticType:[qnco] PreferredName:Plant Leaves SemanticType:[plnt] PreferredName:No effect SemanticType:[qlco] PreferredName:Treatment room SemanticType:[mnob] POS:DT POS:NN POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 8]<Annotation Id="12927" Type="Sentence" StartNode="767" EndNode="943">The effect on incidence is clearly visible in population statistics, leading to an uncompensated increase in breast-cancer incidence of 25 to 50% after 25 years with screening.6PreferredName:Effect SemanticType:[qlco] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Visible SemanticType:[qlco] PreferredName:Population Statistics SemanticType:[qnco] PreferredName:Leading SemanticType:[ftcn] PreferredName:Uncompensated SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:year SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:DT POS:NN POS:IN POS:NN POS:VBZ POS:RB POS:JJ POS:IN POS:NN POS:NNS POS:, POS:VBG POS:TO POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:IN POS:CD POS:TO POS:CD POS:NN POS:IN POS:CD POS:NNS POS:IN POS:NN POS:. 
[sentNum: 9]<Annotation Id="12928" Type="Sentence" StartNode="943" EndNode="1032">6 This is overdiagnosis &#x2014; the detection of cancers that will not cause death or symptoms.PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:Negation SemanticType:[ftcn] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Symptoms SemanticType:[sosy] POS:CD POS:DT POS:VBZ POS:NN POS:IN POS:DT POS:NN POS:IN POS:NNS POS:WDT POS:MD POS:RB POS:VB POS:NN POS:CC POS:NNS POS:. 
[sentNum: 10]<Annotation Id="12929" Type="Sentence" StartNode="1036" EndNode="1169">Although the claimed benefit of screening is thus essentially invisible in population statistics, the major harm is clearly apparent. PreferredName:Benefits SemanticType:[qnco] PreferredName:Trial Screening SemanticType:[resa] PreferredName:Invisible SemanticType:[qlco] PreferredName:Population Statistics SemanticType:[qnco] PreferredName:Major SemanticType:[qlco] PreferredName:apparent SemanticType:[idcn] POS:IN POS:DT POS:VBN POS:NN POS:IN POS:NN POS:VBZ POS:RB POS:RB POS:JJ POS:IN POS:NN POS:NNS POS:, POS:DT POS:JJ POS:NN POS:VBZ POS:RB POS:JJ POS:. 
[sentNum: 11]<Annotation Id="12930" Type="Sentence" StartNode="1170" EndNode="1395">The IARC claim that modeling and case&#x2013;control studies provide evidence of substantially reduced mortality, with little overdiagnosis, is not compatible with observed data or the results of the most reliable randomized trials.PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Reduced SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Small SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Compatible SemanticType:[qlco] PreferredName:Observed SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] PreferredName:Reliability of Results SemanticType:[qlco] PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] POS:DT POS:NN POS:NN POS:WDT POS:NN POS:CC POS:NN POS:NNS POS:VBP POS:NN POS:IN POS:RB POS:VBN POS:NN POS:, POS:IN POS:JJ POS:NN POS:, POS:VBZ POS:RB POS:JJ POS:IN POS:VBN POS:NNS POS:CC POS:DT POS:NNS POS:IN POS:DT POS:RBS POS:JJ POS:VBN POS:NNS POS:. 
[sentNum: 12]<Annotation Id="12931" Type="Sentence" StartNode="1399" EndNode="1585">To the Editor: Lauby-Secretan et al. report that there is sufficient evidence that mammographic screening in women between 70 and 74 years of age reduces breast-cancer&#x2013;related mortality. PreferredName:Editor SemanticType:[ocdi] PreferredName:Report (document) SemanticType:[inpr] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] POS:TO POS:DT POS:NNP POS:: POS:NNP POS:NNP POS:FW POS:FW POS:. POS:NN POS:IN POS:EX POS:VBZ POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:CD POS:CC POS:CD POS:NNS POS:IN POS:NN POS:VBZ POS:JJ POS:NN POS:. 
[sentNum: 13]<Annotation Id="12932" Type="Sentence" StartNode="1586" EndNode="1749">Yet only one of the nine mammographic screening trials reviewed &#x2014; the Swedish Two-County Trial &#x2014; included women who were older than 70 years of age at study entry.1PreferredName:Singular SemanticType:[qnco] PreferredName:One SemanticType:[qnco] PreferredName:Nine SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Senility SemanticType:[fndg] PreferredName:year SemanticType:[tmco] PreferredName:SLC33A1 gene SemanticType:[gngm] PreferredName:Study SemanticType:[resa] PreferredName:Entry (data) SemanticType:[inpr] POS:RB POS:RB POS:CD POS:IN POS:DT POS:CD POS:JJ POS:NN POS:NNS POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NN POS:VBD POS:NNS POS:WP POS:VBD POS:JJR POS:IN POS:CD POS:NNS POS:IN POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 14]<Annotation Id="12933" Type="Sentence" StartNode="1749" EndNode="1986">1 In the Swedish Two-County Trial, women were 40 to 74 years of age at entry, but a subgroup analysis failed to show a reduction in breast-cancer&#x2013;specific mortality for women in the screened group who were 70 to 74 years of age at entry.2PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Entry (data) SemanticType:[inpr] PreferredName:Subset Analysis SemanticType:[resa] PreferredName:Failed SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Show SemanticType:[inpr] PreferredName:Reduced SemanticType:[qlco] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Groups SemanticType:[idcn] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Entry (data) SemanticType:[inpr] POS:CD POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:, POS:NNS POS:VBD POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:IN POS:NN POS:, POS:CC POS:DT POS:NN POS:NN POS:VBD POS:TO POS:VB POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:DT POS:VBN POS:NN POS:WP POS:VBD POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:IN POS:NN POS:. 
[sentNum: 15]<Annotation Id="12934" Type="Sentence" StartNode="1986" EndNode="2189">2 Moreover, mammographic screening results in a substantial rate of overdiagnosis among older women, and this overdiagnosis can lead to unnecessary treatment and an excess of treatment-related mortality.3PreferredName:Mammography finding SemanticType:[fndg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Rate SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Old SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Lead SemanticType:[elii, hops] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:AN 3 SemanticType:[aapp] PreferredName:Mortality, Excess SemanticType:[qnco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] POS:CD POS:RB POS:, POS:JJ POS:NN POS:VBZ POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:IN POS:JJR POS:NNS POS:, POS:CC POS:DT POS:NN POS:MD POS:VB POS:TO POS:JJ POS:NN POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 16]<Annotation Id="12935" Type="Sentence" StartNode="2189" EndNode="2456">3 Given the absence of a clear benefit in reducing breast-cancer&#x2013; specific mortality, and given the potential for increasing treatment-related mortality, mammographic screening in women older than 70 years of age may result in a small increase in all-cause mortality.4PreferredName:Absence (morphologic abnormality) SemanticType:[anab] PreferredName:Clear SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Given name SemanticType:[inpr] PreferredName:Potential SemanticType:[qlco] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Senility SemanticType:[fndg] PreferredName:year SemanticType:[tmco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Small SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Science of Etiology SemanticType:[cnce] PreferredName:Mortality Vital Statistics SemanticType:[qnco] POS:CD POS:VBN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:JJ POS:JJ POS:NN POS:, POS:CC POS:VBN POS:DT POS:NN POS:IN POS:VBG POS:JJ POS:NN POS:, POS:JJ POS:NN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:IN POS:NN POS:MD POS:VB POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 17]<Annotation Id="12936" Type="Sentence" StartNode="2456" EndNode="2554">4 Mammographic screening should not generally be recommended for women older than 70 years of age.PreferredName:Screening mammography SemanticType:[topp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Senility SemanticType:[fndg] PreferredName:year SemanticType:[tmco] POS:CD POS:JJ POS:NN POS:MD POS:RB POS:RB POS:VB POS:VBN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:IN POS:NN POS:. 
[sentNum: 18]<Annotation Id="12937" Type="Sentence" StartNode="2558" EndNode="2652">To the Editor: The IARC Working Group has a generally positive view of mammographic screening. PreferredName:Editor SemanticType:[ocdi] PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Working Group SemanticType:[popg] PreferredName:Positive Finding SemanticType:[fndg] PreferredName:View SemanticType:[spco] PreferredName:Screening mammography SemanticType:[topp] POS:TO POS:DT POS:NNP POS:: POS:DT POS:NN POS:NNP POS:NNP POS:VBZ POS:DT POS:RB POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 19]<Annotation Id="12938" Type="Sentence" StartNode="2653" EndNode="2786">However, the group describes the benefits of mammographic screening in relative terms while referring to the harms in absolute terms. PreferredName:User Group SemanticType:[popg] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Relative SemanticType:[qlco] PreferredName:Term (temporal) SemanticType:[tmco] PreferredName:Referring SemanticType:[ftcn] PreferredName:Absolute SemanticType:[qlco] PreferredName:Term (temporal) SemanticType:[tmco] POS:RB POS:, POS:DT POS:NN POS:VBZ POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:VBG POS:TO POS:DT POS:NNS POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 20]<Annotation Id="12939" Type="Sentence" StartNode="2787" EndNode="2907">Perhaps the merits of the conclusions would be more apparent if all important outcomes were expressed in absolute terms. PreferredName:Conclusion SemanticType:[idcn] PreferredName:More SemanticType:[ftcn] PreferredName:apparent SemanticType:[idcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Absolute SemanticType:[qlco] PreferredName:Term (temporal) SemanticType:[tmco] POS:RB POS:DT POS:NNS POS:IN POS:DT POS:NNS POS:MD POS:VB POS:RBR POS:JJ POS:IN POS:DT POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 21]<Annotation Id="12940" Type="Sentence" StartNode="2908" EndNode="3029">These outcomes might include breast-cancer&#x2013;related mortality, total mortality, false positive results, and overdiagnosis. PreferredName:Result SemanticType:[ftcn] PreferredName:Include (action) SemanticType:[acty] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:% of total SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:overdiagnosis SemanticType:[fndg] POS:DT POS:NNS POS:MD POS:VB POS:JJ POS:NN POS:, POS:JJ POS:NN POS:, POS:JJ POS:JJ POS:NNS POS:, POS:CC POS:NN POS:. 
[sentNum: 22]<Annotation Id="12941" Type="Sentence" StartNode="3030" EndNode="3163">A previous such estimate of the benefits of mammographic screening1 led to the conclusion that the net benefits are marginal at best.PreferredName:Previous SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Mammography SemanticType:[diap] PreferredName:Light Emitting Diode Device Component SemanticType:[mnob] PreferredName:Conclusion SemanticType:[idcn] PreferredName:Reticular SemanticType:[spco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Marginal (quality) SemanticType:[qlco] PreferredName:best (quality) SemanticType:[qlco] POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:IN POS:JJ POS:NN POS:CD POS:VBD POS:TO POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:VBP POS:JJ POS:IN POS:JJS POS:. 
[sentNum: 23]<Annotation Id="12942" Type="Sentence" StartNode="3167" EndNode="3333">The Authors Reply: The members of the IARC Working Group are selected on the basis of subject- matter expertise and absence of real or apparent conflicts of interest. PreferredName:Journalist SemanticType:[prog] PreferredName:member SemanticType:[popg] PreferredName:International Agency for Research on Cancer SemanticType:[hcro] PreferredName:Working Group SemanticType:[popg] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Study Subject SemanticType:[grup] PreferredName:expertise SemanticType:[qlco] PreferredName:Absence (morphologic abnormality) SemanticType:[anab] PreferredName:Actual SemanticType:[qlco] PreferredName:apparent SemanticType:[idcn] PreferredName:Conflict of Interest SemanticType:[idcn] POS:DT POS:NNPS POS:NNP POS:: POS:DT POS:NNS POS:IN POS:DT POS:NN POS:NNP POS:NNP POS:VBP POS:VBN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NN POS:CC POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 24]<Annotation Id="12943" Type="Sentence" StartNode="3334" EndNode="3581">We used literature searches to identify scientists who have published pertinent research related to the interventions being reviewed, including coauthors of randomized, controlled trials and experts who question the use of breast-cancer screening. PreferredName:Used by SemanticType:[fndg] PreferredName:Publications SemanticType:[inpr, mnob] PreferredName:Search - action SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Scientist SemanticType:[prog] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Research Activities SemanticType:[resa] PreferredName:Relationships SemanticType:[qlco] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Disease Screening SemanticType:[diap] POS:PRP POS:VBD POS:NN POS:NNS POS:TO POS:VB POS:NNS POS:WP POS:VBP POS:VBN POS:JJ POS:NN POS:JJ POS:TO POS:DT POS:NNS POS:VBG POS:VBN POS:, POS:VBG POS:NNS POS:IN POS:VBN POS:, POS:VBN POS:NNS POS:CC POS:NNS POS:WP POS:VBP POS:DT POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 25]<Annotation Id="12944" Type="Sentence" StartNode="3582" EndNode="3742">Furthermore, the working group included experts on other screening techniques and on descriptive epidemiology, risk factors, and the treatment of breast cancer. PreferredName:Working Group SemanticType:[popg] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Screen techniques SemanticType:[fndg] PreferredName:And SemanticType:[idcn] PreferredName:Epidemiology, Descriptive SemanticType:[resa] PreferredName:risk factors SemanticType:[qnco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:RB POS:, POS:DT POS:VBG POS:NN POS:VBD POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:IN POS:JJ POS:NN POS:, POS:NN POS:NNS POS:, POS:CC POS:DT POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 26]<Annotation Id="12945" Type="Sentence" StartNode="3743" EndNode="3784">Geographic diversity was also considered.PreferredName:Geographic SemanticType:[spco] PreferredName:Diversity SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] POS:JJ POS:NN POS:VBD POS:RB POS:VBN POS:. 
[sentNum: 27]<Annotation Id="12946" Type="Sentence" StartNode="3786" EndNode="3909">Randomized, controlled trials were reviewed to evaluate the efficacy, but not the effectiveness, of mammographic screening. PreferredName:Randomization SemanticType:[resa] PreferredName:Controlled Clinical Trials as Topic SemanticType:[resa] PreferredName:Reviewed SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Efficacy Study SemanticType:[resa] PreferredName:Negation SemanticType:[ftcn] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] POS:VBN POS:, POS:VBN POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:DT POS:NN POS:, POS:CC POS:RB POS:DT POS:NN POS:, POS:IN POS:JJ POS:NN POS:. 
[sentNum: 28]<Annotation Id="12947" Type="Sentence" StartNode="3910" EndNode="4063">Although evidence from randomized trials is still relevant today, it must be supplemented with the evaluation of evidence from current service screening.PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] PreferredName:Relevance SemanticType:[qlco] PreferredName:Today (temporal qualifier) SemanticType:[tmco] PreferredName:Dietary Supplements SemanticType:[food] PreferredName:evaluation of evidence SemanticType:[resa] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Services SemanticType:[ocac] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:NN POS:IN POS:VBN POS:NNS POS:VBZ POS:RB POS:JJ POS:NN POS:, POS:PRP POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 29]<Annotation Id="12948" Type="Sentence" StartNode="4065" EndNode="4212">In the evaluation of the effectiveness of mammographic screening, high-quality cohort studies were considered to provide the most informative data. PreferredName:Within SemanticType:[spco] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Value Above Reference Range SemanticType:[inpr] PreferredName:Quality SemanticType:[qlco] PreferredName:Cohort Studies SemanticType:[qnco] PreferredName:consider SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Most SemanticType:[qnco] PreferredName:Informative SemanticType:[qlco] PreferredName:Data SemanticType:[idcn] POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:, POS:JJ POS:NN POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:DT POS:RBS POS:JJ POS:NNS POS:. 
[sentNum: 30]<Annotation Id="12949" Type="Sentence" StartNode="4213" EndNode="4554">The working group gave the greatest weight to studies with long follow-up periods and the most robust designs &#x2014; notably, those that accounted for lead time, minimized temporal and geographic differences between screened and unscreened participants, and controlled for individual differences that may have been related to the primary outcome. PreferredName:Working Group SemanticType:[popg] PreferredName:Give - dosing instruction imperative SemanticType:[ftcn] PreferredName:Most SemanticType:[qnco] PreferredName:Weighing patient SemanticType:[diap] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Long SemanticType:[qlco] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Most SemanticType:[qnco] PreferredName:Robust SemanticType:[qlco] PreferredName:Design SemanticType:[acty] PreferredName:Account number:Identifier:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:Lead SemanticType:[elii, hops] PreferredName:Time SemanticType:[tmco] PreferredName:Temporal -Temporal Qualifier SemanticType:[tmco] PreferredName:geographic difference SemanticType:[idcn] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Participant SemanticType:[popg] PreferredName:Control function SemanticType:[ftcn] PreferredName:Individuality SemanticType:[menp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Primary operation SemanticType:[topp] PreferredName:Result SemanticType:[ftcn] POS:DT POS:VBG POS:NN POS:VBD POS:DT POS:JJS POS:NN POS:TO POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:DT POS:RBS POS:JJ POS:NNS POS:VBP POS:RB POS:, POS:DT POS:WDT POS:VBD POS:IN POS:JJ POS:NN POS:, POS:VBN POS:JJ POS:CC POS:JJ POS:NNS POS:IN POS:VBN POS:CC POS:JJ POS:NNS POS:, POS:CC POS:VBN POS:IN POS:JJ POS:NNS POS:WDT POS:MD POS:VB POS:VBN POS:VBN POS:TO POS:DT POS:JJ POS:NN POS:. 
[sentNum: 31]<Annotation Id="12950" Type="Sentence" StartNode="4555" EndNode="4627">These studies account for treatment effects and overdiagnosis by design. PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Account number:Identifier:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:Outcome of Therapy SemanticType:[fndg] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Design SemanticType:[acty] POS:DT POS:NNS POS:VBP POS:IN POS:NN POS:NNS POS:CC POS:NN POS:IN POS:NN POS:. 
[sentNum: 32]<Annotation Id="12951" Type="Sentence" StartNode="4628" EndNode="4840">In addition, the working group specifically evaluated the potential for overdiagnosis and concluded that there is sufficient evidence for overdiagnosis among women who are screened between 50 and 69 years of age.PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Working Group SemanticType:[popg] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Potential SemanticType:[qlco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Age-Years SemanticType:[tmco] POS:IN POS:NN POS:, POS:DT POS:VBG POS:NN POS:RB POS:VBD POS:DT POS:NN POS:IN POS:NN POS:CC POS:VBD POS:IN POS:EX POS:VBZ POS:JJ POS:NN POS:IN POS:NN POS:IN POS:NNS POS:WP POS:VBP POS:VBN POS:IN POS:CD POS:CC POS:CD POS:NNS POS:IN POS:NN POS:. 
[sentNum: 33]<Annotation Id="12952" Type="Sentence" StartNode="4842" EndNode="5009">Case&#x2013;control studies with designs that accounted for the preceding factors were also considered, and their results were largely in line with those from cohort studies. PreferredName:Case-Control Studies SemanticType:[resa] PreferredName:Design SemanticType:[acty] PreferredName:Account number:Identifier:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:Before SemanticType:[tmco] PreferredName:Factor SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Line Specimen SemanticType:[sbst] PreferredName:Cohort Studies SemanticType:[qnco] POS:NN POS:NNS POS:IN POS:NNS POS:WDT POS:VBD POS:IN POS:DT POS:VBG POS:NNS POS:VBD POS:RB POS:VBN POS:, POS:CC POS:PRP$ POS:NNS POS:VBD POS:RB POS:IN POS:NN POS:IN POS:DT POS:IN POS:NN POS:NNS POS:. 
[sentNum: 34]<Annotation Id="12953" Type="Sentence" StartNode="5010" EndNode="5250">On the contrary, most ecologic studies that compared mortality between regions or time periods were judged to be uninformative, since they did not control adequately for potential confounding by secular trends or population characteristics. PreferredName:Ecology SemanticType:[ocdi] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Comparison SemanticType:[acty] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Geographic Locations SemanticType:[geoa] PreferredName:Time periods SemanticType:[tmco] PreferredName:Judge SemanticType:[prog] PreferredName:To SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:control aspects SemanticType:[qlco] PreferredName:Potential SemanticType:[qlco] PreferredName:secular trend SemanticType:[tmco] PreferredName:Population Characteristics SemanticType:[grpa] POS:IN POS:DT POS:NN POS:, POS:JJS POS:JJ POS:NNS POS:IN POS:VBN POS:NN POS:IN POS:NNS POS:CC POS:NN POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:JJ POS:, POS:IN POS:PRP POS:VBD POS:RB POS:VB POS:RB POS:IN POS:JJ POS:JJ POS:IN POS:JJ POS:NNS POS:CC POS:NN POS:NNS POS:. 
[sentNum: 35]<Annotation Id="12954" Type="Sentence" StartNode="5251" EndNode="5324">Modeling studies were not considered for the evaluation of effectiveness.PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Evaluation SemanticType:[ftcn] POS:NN POS:NNS POS:VBD POS:RB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:. 
[sentNum: 36]<Annotation Id="12955" Type="Sentence" StartNode="5326" EndNode="5529">The working group used the same measures for all outcomes (including breast-cancer&#x2013;related mortality and overdiagnosis), since these measures were primarily based on the incidencebased mortality studies. PreferredName:Working Group SemanticType:[popg] PreferredName:Used by SemanticType:[fndg] PreferredName:Same SemanticType:[qlco] PreferredName:Outcome Measures SemanticType:[qnco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Measures SemanticType:[qnco] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Scientific Study SemanticType:[lbpr] POS:DT POS:VBG POS:NN POS:VBD POS:DT POS:JJ POS:NNS POS:IN POS:DT POS:NNS POS:VBP POS:VBG POS:JJ POS:NN POS:CC POS:NN POS:NN POS:, POS:IN POS:DT POS:NNS POS:VBD POS:RB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 37]<Annotation Id="12956" Type="Sentence" StartNode="5530" EndNode="5757">After careful evaluation of the balance between the benefits and adverse effects of mammographic screening, the working group concluded that there is a net benefit from inviting women 50 to 69 years of age to receive screening. PreferredName:Aftercare SemanticType:[hlca] PreferredName:Assessment of sense of balance SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Adverse effects SemanticType:[patf] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Working Group SemanticType:[popg] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Reticular SemanticType:[spco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:To SemanticType:[qlco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Receive SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNS POS:CC POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:, POS:DT POS:VBG POS:NN POS:VBD POS:IN POS:EX POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NNS POS:CD POS:TO POS:CD POS:NNS POS:IN POS:NN POS:TO POS:VB POS:NN POS:. 
[sentNum: 38]<Annotation Id="12957" Type="Sentence" StartNode="5758" EndNode="6013">In addition, the pertinent incidence- based cohort mortality studies consistently reported a substantial reduction in the risk of death from breast cancer among women who were offered or who underwent mammographic screening between 70 and 74 years of age.PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Incidence Studies SemanticType:[qnco] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Cohort SemanticType:[popg] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reporting SemanticType:[hlca] PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:From SemanticType:[qlco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Offered SemanticType:[fndg] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] POS:IN POS:NN POS:, POS:DT POS:JJ POS:NN POS:VBN POS:NN POS:NN POS:NNS POS:RB POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:WP POS:VBD POS:VBN POS:CC POS:WP POS:VBD POS:JJ POS:NN POS:IN POS:CD POS:CC POS:CD POS:NNS POS:IN POS:NN POS:. 
